 Home > Active Ingredient News > Antitumor Therapy > Lynparza is approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

Lynparza is approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

 Last Update: 2021-01-14
 Source: Internet
 Author: User

Tags

pd 1 inhibitor

pancreatic cancer association

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

AstraZeneza and MSD's Lynparza (olaparib) have been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.
specific information on these three approvals: patients with HRD recombinant repair defects (HRD) ovarian cancer, patients with BRCA gene mutation (BRCAm) with anti-resistance prostate cancer (mCRPC), and non-removable pancreatic cancer.
approval by Japan's Ministry of Health, Labour and Industry is based on positive results from clinical trials in PAOLA-1, PROfound, and POLO III, published in the New England Journal of Medicine.
dave Fredrickson, executive vice president of AstraZenecom's oncology division, said: "These three approvals allow Japanese patients to use Lynparza, a targeted therapy for their specific biomarkers.
helps doctors determine treatment options for individual patients to significantly delay the progression of the disease."
Lynparza (olaparib) is the first PARP inhibitor and the first targeted therapy to block DNA damage response (DDR) in cells/tumors with HRR defects such as BRCA1 and/or BRCA2 mutations.
Lynparza's inhibition of PARP causes DNA double strands to break, which in turn contributes to cancer cell death.
Lynparza is being tested in a variety of PARP-dependent tumor types.
。

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.